258 filings
Page 4 of 13
8-K
3ohnr7qsf quh
4 Jun 20
Departure of Directors or Certain Officers
5:17pm
8-K
jua338oyuvk
11 May 20
Acceleron Reports First Quarter 2020 Operating and Financial Results
4:10pm
8-K
inrlk8 gewx1cx2fj
5 May 20
Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
5:06pm
DEFA14A
50rek0dnu ouf3e3a5
16 Apr 20
Additional proxy soliciting materials
4:35pm
8-K
q84s8h
9 Apr 20
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
5:26pm
8-K
t8xy5g0kr67a
7 Apr 20
Departure of Directors or Certain Officers
4:39pm
8-K
yi4uk yeibdz3
6 Apr 20
Other Events
8:41am
8-K
8gf5vh
9 Mar 20
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
4:09pm
S-8
t0w194a 08ja19i5zuid
27 Feb 20
Registration of securities for employees
4:22pm
8-K
zmvpj3 a1
27 Feb 20
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
4:10pm
8-K
puulgq7tc
27 Jan 20
Other Events
4:14pm
8-K
jfxkkcr39
23 Jan 20
Departure of Directors or Certain Officers
4:20pm
8-K
x7efxq134 wi5b4
13 Dec 19
Other Events
4:35pm
8-K
mdu1 n9f2ih30cmpzgo2
9 Dec 19
Other Events
8:04am
8-K
9hw8aaah9
6 Dec 19
Departure of Directors or Certain Officers
5:26pm
8-K
hdzzdp
8 Nov 19
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients
5:27pm